Search Results

You are looking at 51 - 60 of 158 items for :

  • "systemic treatment" x
Clear All
Full access

Richard I. Fisher and Nadia Khan

Lymphomes de l’Adulte . J Clin Oncol 1997 ; 15 : 1110 – 1117 . 3. Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised

Full access

Caron A. Jacobson and Arnold S. Freedman

untreated low-grade non-Hodgkin’s lymphomas . N Engl J Med 1984 ; 311 : 1471 – 1475 . 3. Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

select for cells with high ER expression. In this case report, the imaging studies were observational and not used for treatment decision-making. Nevertheless, these results confirm temporal heterogeneity of ER expression over the course of systemic

Full access

Donna Trauth and Lori J. Goldstein

therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women . N Engl J Med 1988 ; 319 : 1681 – 1692 . 3 Early Breast Cancer Trialists' Collaborative Group . Systemic treatment of early breast cancer by

Full access

Piet Dirix, Lynda Wyld, Shani Paluch-Shimon and Philip Poortmans

benefits from a clinical trial or indeed any systemic treatment, whereas a similar patient at the fifth line of therapy might be expected to benefit substantially less. Still, replacing PS with an alternative that is straightforward but more objective is

Full access

Henry G. Kaplan, Steven Rostad, Jeffrey S. Ross, Siraj M. Ali and Sherri Z. Millis

Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors for which no established systemic treatment exists. MPNSTs occur in approximately 10% of patients with neurofibromatosis type 1, with malignancy usually present in the third or

Full access

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb and William I. Gradishar

is made to confirm the diagnosis and tumor pathologic profile (estrogen receptor, progesterone receptor, and HER2 status). Systemic Treatment of Recurrent or Stage IV Disease Recommendations: The committee recommends administering adjuvant

Full access

Carol D. Morris

Osteosarcoma Group (EURAMOS) is randomizing postoperative systemic treatment to additional ifosfamide and etoposide, or interferon-α based on specimen necrosis. The benefit of this approach for treating patients with pelvic tumors is currently unknown

Full access

Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon and Danny Rischin

than 6 months. From a molecular perspective, TP53 mutations have been commonly reported in ATC, but given the lack of effective systemic treatment options for the disease, it has been of particular interest to note reports of the identification of

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar

predictive biomarkers by providing tumor specimens and blood samples before and during systemic treatment. Selection of Patients for Preoperative Therapy Not all patients are appropriate candidates for preoperative systemic therapy. According to the